TransMedics Group, Inc. (TMDX) Operating Cash Flow CAGR:345.96%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over the past 12 months, TransMedics Group, Inc.'s Operating Cash Flow CAGR is 345.96%.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash TransMedics Group, Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
TMDX Operating Cash Flow CAGR Chart
TransMedics Group, Inc. (TMDX)
TMDX Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
TMDX Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $48.80M | $192.84M | +$144.04M | +295.14% | +295.14% |
| 2024 | $-13.03M | $48.80M | +$61.83M | N/A | N/A |
| 2023 | $-45.82M | $-13.03M | +$32.79M | N/A | N/A |
| 2022 | $-28.86M | $-45.82M | $-16.95M | N/A | N/A |
| 2021 | $-30.27M | $-28.86M | +$1.40M | N/A | N/A |
| 2020 | $-32.29M | $-30.27M | +$2.02M | N/A | N/A |
| 2019 | $-25.98M | $-32.29M | $-6.30M | N/A | N/A |
| 2018 | $-23.10M | $-25.98M | $-2.89M | N/A | N/A |
| 2017 | $-24.11M | $-23.10M | +$1.01M | N/A | N/A |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $24.53M | -28.9% | — |
| Q4 2025 | $34.51M | -50.4% | +75.5% |
| Q3 2025 | $69.57M | -24.1% | +914.6% |
| Q2 2025 | $91.61M | — | +256.2% |
| Q1 2025 | -$2.85M | — | +16.9% |
| Q4 2024 | $19.66M | +186.8% | +136.8% |
| Q3 2024 | $6.86M | -73.3% | — |
| Q2 2024 | $25.72M | — | — |
| Q1 2024 | -$3.44M | — | +60.3% |
| Q4 2023 | $8.30M | — | — |
| Q3 2023 | -$6.87M | -18.4% | +51.9% |
| Q2 2023 | -$5.80M | +33.0% | +36.2% |
| Q1 2023 | -$8.66M | -114.6% | +52.9% |
| Q4 2022 | -$4.04M | +71.7% | +39.3% |
| Q3 2022 | -$14.28M | -57.0% | -52.7% |
| Q2 2022 | -$9.09M | +50.6% | -64.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein